All In Biotech

Drug Trial Radar · NCT07662395

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

A Multicenter Phase II/III Study Evaluating the Efficacy and Safety of SCTB41 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Driver-Negative Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

410

Planned (sponsor's estimate)

Start

May 9, 2026

Primary completion

Jan 24, 2030

Study completion Jan 24, 2030

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter Phase II/III study evaluating the efficacy and safety of SCTB41 combined with chemotherapy versus tislelizumab combined with chemotherapy as first-line treatment in patients with driver-negative locally advanced or metastatic non-small cell lung cancer (NSCLC). The Phase II portion is an open-label safety run-in study enrolling approximately 30-60 patients to evaluate the safety and tolerability of SCTB41 plus chemotherapy. Following confirmation of acceptable safety and preliminary efficacy, the study will proceed to the Phase III portion. The Phase III portion is a randomized, double-blind, active-controlled study enrolling approximately 350 patients. Eligible participants will be randomized in a 1:1 ratio to receive SCTB41 plus chemotherapy or tislelizumab plus chemotherapy. The primary objective is to compare progression-free survival assessed by blinded independent central review according to RECIST version 1.1.

Conditions

  • Double Blind

Interventions

  • SCTB41Drug

    IV infusion,Specified dose on specified days.

  • TislelizumabDrug

    IV infusion,Specified dose on specified days.

  • PaclitaxelDrug

    175 mg/m², IV infusion, Q3W, for 4 cycles.

  • Nab-paclitaxelDrug

    100 mg/m², IV infusion, on Days 1, 8, 15 of each 3-week cycle, for 4 cycles

  • CarboplatinDrug

    AUC 5, IV infusion, Q3W, for 4 cycles.

  • CisplatinDrug

    75 mg/m², IV infusion, Q3W, for 4 cycles.

  • PemetrexedDrug

    500 mg/m², IV infusion, Q3W, for 4 cycles .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 24 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.